BSR_03_0022_A2_S92
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- E2F_TARGETS+0.360
- MTORC1_SIGNALING+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.350
- CHOLESTEROL_HOMEOSTASIS+0.340
- G2M_CHECKPOINT+0.280
- ANDROGEN_RESPONSE+0.220
- DNA_REPAIR+0.220
- ADIPOGENESIS+0.210
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.390
- INTERFERON_GAMMA_RESPONSE-0.210
- WNT_BETA_CATENIN_SIGNALING-0.200
- KRAS_SIGNALING_UP-0.180
- IL2_STAT5_SIGNALING-0.160
- IL6_JAK_STAT3_SIGNALING-0.150
- KRAS_SIGNALING_DN-0.150
- HEDGEHOG_SIGNALING-0.140
- TNFA_SIGNALING_VIA_NFKB-0.140
- COMPLEMENT-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A23H-01A-11R-A157-07 | — | C | 0.810 |
| 2 | TCGA-78-7150-01A-21R-2039-07 | — | cohortA4 | 0.789 |
| 3 | TCGA-D8-A1XJ-01A-11R-A14M-07 | — | C | 0.778 |
| 4 | SRR934967 | — | — | 0.751 |
| 5 | TCGA-C8-A12Z-01A-11R-A115-07 | — | C | 0.749 |
| 6 | TCGA-E9-A1N6-01A-11R-A144-07 | — | C | 0.745 |
| 7 | DRR168580 | — | — | 0.745 |
| 8 | SRR12696752 | — | — | 0.743 |
| 9 | SRR5903549 | — | cohortA4 | 0.742 |
| 10 | SRR8518424 | — | C | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |